^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TQB3455

    i
    Other names: TQB3455
    Company:
    Sino Biopharm
    Drug class:
    IDH2 inhibitor
    Related drugs:
    2years
    Phase I Study of TQB3455, a Selective Inhibitor of IDH2 with Favorable Safety and More Potent Efficacy to IDH2-R172K Mutation, for Acute Myeloid Leukemia and Myelodysplastic Syndrome (ASH 2022)
    Enasidenib (ENA), the first selective IDH2 inhibitor, was associated with impressive response rates in relapsed/refractory (R/R) AML and was approved by FDA in 2017. TQB3455 is well-tolerated for myeloid malignancy at the R2PD of 100 mg qd. It also yield high rates of clinical response in pts with mIDH2 AML. Patients with IDH2-R172K mutation fared much better than IDH2-R140Q/W with regard to response, this is in line with outcome of TQB3455 in vitro but different from previous reports of ENA.
    Clinical • P1 data
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation • RAS mutation • IDH2 R172K • IDH2 R140Q • IDH2 R172
    |
    Idhifa (enasidenib) • TQB3455
    over4years
    A Study of TQB3455 Tablets in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=50, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation
    |
    TQB3455
    over4years
    A Study of TQB3455 Tablets in Subjects With Advanced Malignancies (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Clinical • New P1 trial
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH2 mutation
    |
    TQB3455